HCA
ALNY icon

Harbor Capital Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Harbor Capital Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$514K Buy
1,708
+4
+0.2% +$1.21K 0.04% 521
2026
Q1 		$564K Buy
+1,704
New +$580K 0.05% 458
2025
Q1 		– Sell
-2,650
Closed -$624K – 1405
2024
Q4 		$624K Buy
2,650
+63
+2% +$16.6K 0.03% 522
2024
Q3 		$712K Buy
2,587
+9
+0.3% +$2.34K 0.03% 514
2024
Q2 		$626K Buy
2,578
+10
+0.4% +$1.58K 0.05% 478
2024
Q1 		$384K Sell
2,568
-370
-13% -$61.7K 0.05% 466
2023
Q4 		$562K Buy
2,938
+51
+2% +$8.69K 0.11% 227
2023
Q3 		$511K Buy
2,887
+163
+6% +$31.1K 0.11% 225
2023
Q2 		$517K Sell
2,724
-14
-0.5% -$2.78K 0.1% 240
2023
Q1 		$548K Buy
2,738
+2,363
+630% +$497K 0.16% 133
2022
Q4 		$89.1K Sell
375
-22
-6% -$4.69K 0.09% 91
2022
Q3 		$79K Sell
397
-811
-67% -$155K 0.07% 107
2022
Q2 		$176K Buy
1,208
+108
+10% +$15.3K 0.13% 85
2022
Q1 		$180K Buy
+1,100
New +$168K 0.08% 98

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Harbor Capital Advisors's ALNY Position: Q2 2026 in Review

Harbor Capital Advisors increased its Alnylam Pharmaceuticals (ALNY) stake by 0.23% in Q2 2026, buying an estimated $1.21K and bringing the position to 1,708 shares worth $514K. The position accounts for 0.04% of the portfolio, ranked #521.

Harbor Capital Advisors first reported a position in ALNY in Q1 2022 and has held it in 14 quarters since. The position peaked at $712K in Q3 2024. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Harbor Capital Advisors held 1,708 shares of Alnylam Pharmaceuticals worth $514K as of Q2 2026.
  • Harbor Capital Advisors bought 4 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $1.21K.
  • Alnylam Pharmaceuticals made up 0.04% of Harbor Capital Advisors's portfolio in Q2 2026, its #521 holding.
  • Harbor Capital Advisors first reported a position in Alnylam Pharmaceuticals in Q1 2022 and has held it in 14 quarters since.
  • Harbor Capital Advisors's Alnylam Pharmaceuticals position peaked at $712K in Q3 2024.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Harbor Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.